Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study
Urol Oncol. 2012 Jul-Aug;30(4):408-14.
Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ.
Octreotide acetato depot è stato valutato in modo prospettico in pazienti con carcinoma della prostata, non metastatico, resistente alla castrazione (CRPC).
Octreotide acetato depot/carcinoma prostatico.
